CCR4 and neoplasm: While clinical efficacy did not correlate with PDL-1 or CCR4 expression levels on tumour cells, the number of TIL or the mutational burden, Mogamulizumab reduced the proportion of Treg and increased the proportion of CTL in on-treatment biopsies compared to baseline.